Results 21 to 30 of about 15,701 (194)

Efficacy and Safety of Empagliflozin in Type 1 Diabetes Mellitus Patients: A Systematic Review

Endocrinology Research and Practice, 2021
As the efficacy and safety of empagliflozin remain poorly studied in Type 1 diabetes mellitus (T1DM) patients, this narrative-systematic review aims to review it.
Sumanta SAHA, Sujata SAHA
doaj   +1 more source

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

Frontiers in Pharmacology, 2022
The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and ...
Alana Aragón-Herrera, Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Manuel Campos-Toimil, Tomás García-Caballero, Luis Barral, Estefanía Tarazón, Estefanía Tarazón, Esther Roselló-Lletí, Esther Roselló-Lletí, Manuel Portolés, Manuel Portolés, Oreste Gualillo, Isabel Moscoso, Ricardo Lage, José Ramón González-Juanatey, José Ramón González-Juanatey, Sandra Feijóo-Bandín, Sandra Feijóo-Bandín, Francisca Lago, Francisca Lago   +22 more
doaj   +1 more source

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease

Biomedicines, 2022
Gliflozins (sodium-glucose transporter-2 inhibitors) exhibited renoprotective effects not only in diabetic but also in non-diabetic patients with chronic kidney disease (CKD). Controversial results were reported in experimental non-diabetic models of CKD.
Silvie Hojná, Zoe Kotsaridou, Zdeňka Vaňourková, Hana Rauchová, Michal Behuliak, Petr Kujal, Michaela Kadlecová, Josef Zicha, Ivana Vaněčková   +8 more
doaj   +1 more source

1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome

Journal of the Saudi Heart Association, 2017
Clinical Research. Presentation type: Poster Presentation. Introduction: Empagliflozin is a potent and selective SGLT2-I used in the treatment of T2DM.
Mahmoud Elrouby, Elvira Toural
doaj   +1 more source

Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice

iScience, 2023
Summary: Obesity has become a global epidemic, associated with several chronic complications. The intestinal microbiome is a critical regulator of metabolic homeostasis and obesity.
Junfeng Shi, Hongyan Qiu, Qian Xu, Yuting Ma, Tongtong Ye, Zengguang Kuang, Na Qu, Chengxia Kan, Ningning Hou, Fang Han, Xiaodong Sun   +10 more
doaj   +1 more source

Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet‐Derived Growth Factor–Related Signaling

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events. However, the precise mechanisms beyond glycemic control are not fully understood.
Gwo‐Jyh Chang, Wei‐Jan Chen, Yu‐Juei Hsu, Ying‐Hwa Chen   +3 more
doaj   +1 more source

Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy

Antioxidants
Carfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients. However, carfilzomib treatment is associated with cardiovascular complications.
Mina Y. George, Mohamed S. Dabour, Eman Rashad, Beshay N. Zordoky   +3 more
doaj   +1 more source

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. [PDF]

PLoS ONE, 2017
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associated with slower progression of diabetic kidney disease.
David Cherney, Bruce A Perkins, Yuliya Lytvyn, Hiddo Heerspink, María E Rodríguez-Ortiz, Harald Mischak   +5 more
doaj   +1 more source

Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China

Frontiers in Cardiovascular Medicine, 2022
BackgroundThe Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) is the first randomized controlled trial to provide promising evidence on the efficacy of adding empagliflozin to the ...
Yaohui Jiang, Jun Xie
doaj   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source